Fig. 3From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in TaiwanEnd stage renal disease free rates stratified by chronic kidney disease or not for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ESRD end stage renal disease, CKD chronic kidney diseaseBack to article page